Janis Racevskis.

Hugo F pde5 inhibitor . Fernandez, M.D., Zhuoxin Sun, Ph.D., Xiaopan Yao, Ph.D., Mark R. Litzow, M.D., Selina M. Luger, M.D., Elisabeth M. Paietta, Ph.D., Janis Racevskis, Ph.D., Gordon W. Dewald, Ph.D., Rhett P. Ketterling, M.D., John M. Bennett, M.D., Jacob M. Rowe, M.D., Hillard M. Lazarus, M.D., and Martin S. Tallman, M.D.: Anthracycline Dosage Intensification in Acute Myeloid Leukemia The survival of sufferers with acute myeloid leukemia is suffering from many variables, including therapy that induces complete remission and appropriate consolidation therapy. Currently, cytarabine in addition anthracycline is the typical induction therapy for individuals with AML.1 The widely used intravenous mix of daunorubicin , given daily for 3 times, and cytarabine , given daily for seven days, results in complete remission in 50 to 75 percent of patients.1,2 Neither the addition of other drugs to daunorubicin and cytarabine3 nor intensification of the dosage of cytarabine4-6 has been shown to improve the results.